Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology and NeurologyLive, and for quickly transforming acquisitions into high-functioning business units. Follow him on X @SilasInman, LinkedIn, sinman@mjhlifesciences.com.

Articles

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

May 22nd 2018

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, which is nearly double the historical expectations for patients with the disease.

FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma

May 19th 2018

The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer

May 17th 2018

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma

May 8th 2018

The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Regorafenib HCC Benefits Consistent in Additional Analyses

April 30th 2018

Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.

FDA Approves Fostamatinib for Chronic ITP

April 18th 2018

The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.

Nivolumab OS Benefit Sustained in Long-Term Follow-Up for SCCHN

April 17th 2018

Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Crizotinib Confirmed as Standard of Care for ALK+ Inflammatory Myofibroblastic Tumors

April 16th 2018

Treatment with crizotinib elicited an objective response rate of 50% for patients with ALK-positive advanced, inoperable inflammatory myofibroblastic tumor.

Abemaciclib Data Reviewed as New Breast Cancer Indications Added

March 12th 2018

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

PARP Inhibitors Arrive for BRCA+ Breast Cancer

March 11th 2018

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

Olaparib Breast Cancer Efficacy Highlighted in Added Analyses

March 8th 2018

Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma

February 21st 2018

The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.

FDA Grants Priority Review to Ivosidenib for IDH1+ AML

February 15th 2018

The FDA has granted a priority review designation to ivosidenib (AG-120) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration

February 15th 2018

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

FDA Approves Abiraterone for High-Risk Prostate Cancer

February 8th 2018

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

February 6th 2018

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

Celgene Acquiring Juno Therapeutics for $9 Billion

January 22nd 2018

Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.

FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

January 22nd 2018

The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer

January 20th 2018

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.